Literature DB >> 11220749

Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene.

P Pastor1, E Pastor, C Carnero, R Vela, T García, G Amer, E Tolosa, R Oliva.   

Abstract

Heterozygous missense and splice-site mutations in the tau gene have been previously identified in familial frontotemporal dementia with autosomal dominant inheritance. Here we report a Spanish kindred in which two brothers born from a third-degree consanguineous marriage were both affected with atypical progressive supranuclear palsy. A homozygous deletion at codon 296 (delN296) was identified in one of the affected siblings. Among the heterozygous carriers, two members with probable Parkinson's disease were identified, but none of heterozygotes developed atypical parkinsonism. The delN296 mutation lies in the sequence corresponding to the second tubulin-binding repeat of tau protein and affects one asparagine residue absolutely conserved in other species. This finding indicates that homozygous mutations in the tau gene may also cause hereditary tauopathies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220749     DOI: 10.1002/1531-8249(20010201)49:2<263::aid-ana50>3.0.co;2-k

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  29 in total

Review 1.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

2.  Mutations in tau gene exon 10 associated with FTDP-17 alter the activity of an exonic splicing enhancer to interact with Tra2 beta.

Authors:  Zhihong Jiang; Hao Tang; Necat Havlioglu; Xiaochun Zhang; Stefan Stamm; Riqiang Yan; Jane Y Wu
Journal:  J Biol Chem       Date:  2003-03-20       Impact factor: 5.157

3.  Parkinsonism and frontotemporal dementia: the clinical overlap.

Authors:  Alberto J Espay; Irene Litvan
Journal:  J Mol Neurosci       Date:  2011-09-03       Impact factor: 3.444

4.  Novel L284R MAPT mutation in a family with an autosomal dominant progressive supranuclear palsy syndrome.

Authors:  Jonathan D Rohrer; Dominic Paviour; Jana Vandrovcova; John Hodges; Rohan de Silva; Martin N Rossor
Journal:  Neurodegener Dis       Date:  2010-09-14       Impact factor: 2.977

Review 5.  Mitochondrial dysfunction as a therapeutic target in progressive supranuclear palsy.

Authors:  Vincent Ries; Wolfgang H Oertel; Günter U Höglinger
Journal:  J Mol Neurosci       Date:  2011-07-27       Impact factor: 3.444

6.  Three sib-pairs of autopsy-confirmed progressive supranuclear palsy.

Authors:  Shinsuke Fujioka; Monica Y Sanchez Contreras; Audrey J Strongosky; Kotaro Ogaki; Nathaniel Robb Whaley; Pawel M Tacik; Jay A van Gerpen; Ryan J Uitti; Owen A Ross; Zbigniew K Wszolek; Rosa Rademakers; Dennis W Dickson
Journal:  Parkinsonism Relat Disord       Date:  2014-11-15       Impact factor: 4.891

7.  The tauopathy associated with mutation +3 in intron 10 of Tau: characterization of the MSTD family.

Authors:  Salvatore Spina; Martin R Farlow; Frederick W Unverzagt; David A Kareken; Jill R Murrell; Graham Fraser; Francine Epperson; R Anthony Crowther; Maria G Spillantini; Michel Goedert; Bernardino Ghetti
Journal:  Brain       Date:  2007-12-07       Impact factor: 13.501

8.  No evidence of PGRN or MAPT gene dosage alterations in a collection of patients with frontotemporal lobar degeneration.

Authors:  Lena Skoglund; Sofie Ingvast; Toshifumi Matsui; Stefanie H Freeman; Matthew P Frosch; Rosemarie Brundin; Vilmantas Giedraitis; John H Growdon; Bradley T Hyman; Lars Lannfelt; Martin Ingelsson; Anna Glaser
Journal:  Dement Geriatr Cogn Disord       Date:  2009-11-23       Impact factor: 2.959

Review 9.  Chasing genes in Alzheimer's and Parkinson's disease.

Authors:  Aida M Bertoli-Avella; Ben A Oostra; Peter Heutink
Journal:  Hum Genet       Date:  2004-03-04       Impact factor: 4.132

Review 10.  Alternative splicing of exon 10 in the tau gene as a target for treatment of tauopathies.

Authors:  Jianhua Zhou; Qingming Yu; Tie Zou
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.